|Mr. Jerome D. Jabbour J.D.||Co-Founder, CEO, Pres & Director||450.46k||N/A||1974|
|Dr. Raphael J. Mannino||Sr. VP & Chief Scientific Officer||240k||N/A||1947|
|Mr. Keith A. Kucinski CPA, M.B.A.||Chief Financial Officer||N/A||N/A||1970|
|Dr. Theresa Matkovits||Chief Devel. Officer||N/A||N/A||1967|
|Mr. Frank Calamusa||Exec. Director and Head of Manufacturing & Supply Chain||N/A||N/A||N/A|
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company develops products using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals, which could encapsulate small molecules, gene therapies, vaccines, proteins, and peptides. The company's lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. In addition, it provides MAT2501, an orally administered cochleate formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with ViiV Healthcare for the treatment and care for people living with human immunodeficiency virus. The company was founded in 2013 and is based in Bedminster, New Jersey.
Matinas BioPharma Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.